Know Cancer

forgot password

LCCC 0215: Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Support Followed by Conformal Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung

Phase 2
18 Years
Not Enrolling
Non Small Cell Lung Cancer

Thank you

Trial Information

LCCC 0215: Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Support Followed by Conformal Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung

Lung cancer remains the leading cause of cancer-related mortality in the United States. In
2002, approximately 170,000 new cases of lung cancer will be diagnosed, and approximately
160,000 deaths will occur. Eighty percent of cases of lung cancer are of the non-small cell
type, and 30 to 35% will be Stage IIIA/B and are considered potentially curable. The
standard of care in the United States for those patients with unresectable Stage IIIA/B and
a good performance status (PS) is a combination of systemic chemotherapy and thoracic
radiation therapy (TRT). What is not clear in the management of these patients is the
optimal strategy to employ in the combined-modality approach, as well as the optimal
chemotherapy and radiation therapy dose and schedule.

Induction and Concurrent Chemoradiation Therapy for Stage IIIA/B NSCLC The use of combined
modality has become the standard of care in unresectable Stage IIIA/B non-small cell lung
cancer (NSCLC). In the curative approach to this disease, both local control and eradication
of occult micrometastatic disease must be achieved. Combined-modality trials employing
induction chemotherapy have suggested a reduction in the rate of metastatic disease,
suggesting that effectively delivered chemotherapy can eradicate occult micrometastatic
disease. All of the trials cited have shown improved survival for the combined-modality arm.
Combined-modality trials employing concurrent chemoradiation have suggested improved
loco-regional control resulting in improved survival. These data suggest that both induction
and concurrent treatment may be important and may exert their benefit in different manners:
induction therapy with effective chemotherapy reduces the rate of overt metastatic disease,
while concurrent treatment improves local control by enhancing the local effect of TRT. Four
trials to date have been published addressing sequential versus concurrent therapy. In these
trials, concurrent treatment yielded improved survival over the sequential approach. The
value of either induction or consolidation therapy in addition to concurrent chemotherapy is
currently being addressed in randomized Phase III trials.

The study will evaluate the incorporation of ZD1839 with concurrent CP and TCRT to a dose of
74 Gy following 2 cycles of induction CIP. The primary objective will be to define the
toxicity profile of this approach. With amendment 2, patients will no longer receive
maintenance ZD1839. Given the data generated on LCCC 9603 and 2001, this "hybrid" platform
of induction CIP followed by concurrent TCRT (74 Gy) and CP seems appropriate for
incorporation of ZD1839 because of the general tolerance of this therapy in good PS,
unresectable, Stage III NSCLC subjects. Given that esophagitis is the primary toxicity seen
with this approach, stopping rules will be in place for excessive esophageal toxicity.

Inclusion Criteria:

1. Subjects 18 years of age or older.

2. Subjects with histologically or cytologically confirmed NSCLC that is considered
generally unresectable or inoperable. No prior chemotherapy for NSCLC or thoracic
radiotherapy is allowed.

3. Subjects with Stage IIIA or IIIB disease (clinically or surgically staged).

4. Subject with disease designated T3, N0-N1 based on mediastinal invasion or proximity
to the carina.

Subjects with contralateral mediastinal disease (N3) are eligible if all gross
disease can be encompassed within the radiation port.

5. Subjects with pleural fluid that is a transudate and is cytologically negative.

6. Subjects with pleural effusions that are seen only on CT scan and are too small to

7. Subjects with measurable or evaluable disease.

8. Subjects with PS of 0 or 1 by the ECOG scale (see Appendix 2).

9. Subjects with laboratory values as follows:

Absolute granulocyte count: ≥1,500/µL Platelets: ≥100,000/µL Total bilirubin: ≤1.5 x
institutional upper normal limit Serum creatinine: <1.6 mg/dL or Creatinine
clearance:>40 mL/min

AST and ALT: ≤2.5 x institutional upper normal limit FEV 1 >800 cc

10. Subjects must be nonpregnant and non-lactating. Subjects of childbearing potential
must implement an effective method of contraception during the study. All female
subjects, except those who are postmenopausal or surgically sterilized, must have a
negative pre-study serum or urine pregnancy test.

11. Subjects must have a life expectancy > 2 months.

12. Subjects must be seen by both a medical oncologist and a radiation oncologist before

13. Subjects must be informed of the investigational nature of the study and must sign an
informed consent form.

Exclusion Criteria:

1. Subjects with disease designated T3, N0-N1 based on chest wall invasion, subjects
with N3 supraclavicular disease, or subjects with superior sulcus tumors.

2. Subjects with cytologically positive pleural effusions.

3. Subjects who have received prior chemotherapy or radiochemotherapy for lung cancer or
prior chest radiotherapy.

4. Subjects who are < 3 weeks since formal exploratory thoracotomy.

5. Subjects with a history of other cancers except in situ carcinoma of the cervix or
breast, inactive nonmelanomatous skin cancer, or other cancer, unless the subject has
been free of disease for > 5 years.

Also, exceptions can be made by the PI for a subject with a malignancy for which the
prognosis is substantially better than the subject's prognosis for NSCLC.

6. Subjects with an active serious infection or other serious underlying medical
condition that would otherwise impair their ability to receive protocol treatment.
Subjects with post-obstructive pneumonia remain eligible.

7. Subjects with dementia or significantly altered mental status that would prohibit the
understanding and/or giving of informed consent.

8. Pregnant or breast-feeding females or subjects not using adequate methods of birth

9. Subjects receiving other investigational therapy or non-approved therapy within 30
days before Day 1 of protocol treatment.

10. Subjects with known hypersensitivity to E coli-derived proteins, pegfilgrastim, or
any component of the product will be excluded.

11. Subjects with metastatic disease are excluded.

12. Subjects taking phenytoin, rifampicin, barbiturates, carbamazepine, or St. John's

13. Any evidence of clinically active ILD (subjects with chronic stable radiographic
changes who are asymptomatic need not be excluded).

14. Subjects with evidence of any other significant clinical disorder or laboratory
finding that makes it undesirable for the subject to participate in the trial.

15. As judged by the investigator, subjects with any evidence of severe or uncontrolled
systemic disease (eg, unstable or uncompensated respiratory, cardiac, hepatic, or
renal disease).

16. Subjects with known severe hypersensitivity to ZD1839 or any of the excipients of
this product.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of subjects experiencing toxicity

Outcome Description:

Toxicity of the combination of induction carboplatin/paclitaxel/irinotecan, followed by concurrent carboplatin/paclitaxel/ZD1839 and high-dose TCRT, will be assessed by CTCAE criteria

Outcome Time Frame:

60 days

Safety Issue:


Principal Investigator

David Morris, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of North Carolina, Chapel Hill


United States: Institutional Review Board

Study ID:

LCCC 0215



Start Date:

November 2003

Completion Date:

October 2010

Related Keywords:

  • Non Small Cell Lung Cancer
  • unresectable
  • induction
  • radiotherapy
  • ZD1839
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



University of North Carolina Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina  27599